Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Scam not!/theInformer ... ur2lurking
11
Dec 01, 2009 06:24PM
8
Dec 01, 2009 06:41PM

Dec 01, 2009 09:01PM
2
Dec 01, 2009 11:46PM
2
Dec 02, 2009 12:31AM

Dec 02, 2009 02:24AM

HDVY is nothing like PTSC in any way, shape, or form, other than having patents.

Here's one little red flag that you may have missed:

The Company received letters from an investor in the Company’s 2007 private placement (“2007 Private Placement”), claiming, among other things, that its anti-dilution rights received in the 2007 Private Placement had been triggered by various amendments to the vesting provisions of outstanding warrants and that, as a result, it is entitled to receive additional shares of Company common stock for no additional consideration. While the Company denies the allegations and believes they are without merit, if the investor’s position is correct, the Company may be required, among other things, to issue approximately 98,500,000 shares to such investor, and, if all of the other investors in the 2007 Private Placement sought the same remedy, the Company may be required to issue approximately 739,000,000 shares in the aggregate. Issuing such shares of common stock would cause substantial dilution to existing shareholders and would exceed the number of the Company’s authorized shares of common stock.

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6895611

You might like to check the 10K:

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note M, the Company has had limited revenue since inception, has incurred recurring losses from operations, and has had to continually seek additional capital investment in order to fund operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note M. The financial statements do not include any adjustments that might result from the outcome of this uncertainty

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6514776

Caveat emptor!

Be well

5
Dec 02, 2009 08:05AM
1
Dec 02, 2009 09:07AM
4
Dec 02, 2009 10:00AM
2
Dec 02, 2009 10:10AM
4
Dec 02, 2009 11:45AM
Share
New Message
Please login to post a reply